|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NRD1 |
Gene summary for NRD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NRD1 | Gene ID | 4898 |
| Gene name | nardilysin convertase | |
| Gene Alias | NRD1 | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | O43847 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4898 | NRD1 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 4.40e-03 | 4.25e-01 | 0.1557 |
| 4898 | NRD1 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 1.29e-04 | 5.48e-01 | 0.159 |
| 4898 | NRD1 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 9.04e-14 | 9.28e-01 | 0.1479 |
| 4898 | NRD1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.44e-14 | 5.02e-01 | 0.1633 |
| 4898 | NRD1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.37e-13 | 4.47e-01 | 0.1608 |
| 4898 | NRD1 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 4.78e-16 | 5.61e-01 | 0.1604 |
| 4898 | NRD1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.12e-19 | 6.27e-01 | 0.1621 |
| 4898 | NRD1 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.27e-04 | 4.17e-01 | 0.1619 |
| 4898 | NRD1 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 1.03e-11 | 6.97e-01 | 0.159 |
| 4898 | NRD1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 2.89e-06 | 3.28e-01 | 0.1602 |
| 4898 | NRD1 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 1.73e-03 | 6.92e-01 | 0.1439 |
| 4898 | NRD1 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 5.58e-07 | 5.00e-01 | 0.1608 |
| 4898 | NRD1 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 6.72e-08 | 6.16e-01 | 0.1622 |
| 4898 | NRD1 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.98e-11 | 4.40e-01 | 0.1575 |
| 4898 | NRD1 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 1.92e-10 | 4.64e-01 | 0.1545 |
| 4898 | NRD1 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.82e-05 | 3.56e-01 | 0.1569 |
| 4898 | NRD1 | P1_cSCC | Human | Skin | cSCC | 8.59e-28 | 9.34e-01 | 0.0292 |
| 4898 | NRD1 | P2_cSCC | Human | Skin | cSCC | 2.03e-20 | 6.02e-01 | -0.024 |
| 4898 | NRD1 | P4_cSCC | Human | Skin | cSCC | 5.50e-50 | 9.68e-01 | -0.00290000000000005 |
| 4898 | NRD1 | P10_cSCC | Human | Skin | cSCC | 1.21e-45 | 1.20e+00 | 0.1017 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00988699 | Cervix | CC | cellular oxidant detoxification | 30/2311 | 101/18723 | 2.72e-06 | 7.93e-05 | 30 |
| GO:19907489 | Cervix | CC | cellular detoxification | 30/2311 | 116/18723 | 5.34e-05 | 7.94e-04 | 30 |
| GO:00073695 | Cervix | CC | gastrulation | 42/2311 | 185/18723 | 5.83e-05 | 8.46e-04 | 42 |
| GO:00972379 | Cervix | CC | cellular response to toxic substance | 31/2311 | 124/18723 | 8.09e-05 | 1.10e-03 | 31 |
| GO:00096369 | Cervix | CC | response to toxic substance | 52/2311 | 262/18723 | 3.34e-04 | 3.52e-03 | 52 |
| GO:00987549 | Cervix | CC | detoxification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
| GO:0001704 | Cervix | CC | formation of primary germ layer | 27/2311 | 121/18723 | 1.49e-03 | 1.16e-02 | 27 |
| GO:00454549 | Cervix | CC | cell redox homeostasis | 10/2311 | 35/18723 | 7.99e-03 | 4.18e-02 | 10 |
| GO:009723710 | Endometrium | AEH | cellular response to toxic substance | 34/2100 | 124/18723 | 5.02e-07 | 1.97e-05 | 34 |
| GO:199074810 | Endometrium | AEH | cellular detoxification | 30/2100 | 116/18723 | 8.40e-06 | 1.98e-04 | 30 |
| GO:000963610 | Endometrium | AEH | response to toxic substance | 52/2100 | 262/18723 | 2.89e-05 | 5.40e-04 | 52 |
| GO:009886910 | Endometrium | AEH | cellular oxidant detoxification | 26/2100 | 101/18723 | 3.57e-05 | 6.26e-04 | 26 |
| GO:004545410 | Endometrium | AEH | cell redox homeostasis | 12/2100 | 35/18723 | 2.69e-04 | 3.12e-03 | 12 |
| GO:009875410 | Endometrium | AEH | detoxification | 31/2100 | 152/18723 | 6.85e-04 | 6.62e-03 | 31 |
| GO:009723715 | Endometrium | EEC | cellular response to toxic substance | 35/2168 | 124/18723 | 3.44e-07 | 1.37e-05 | 35 |
| GO:199074815 | Endometrium | EEC | cellular detoxification | 31/2168 | 116/18723 | 5.54e-06 | 1.36e-04 | 31 |
| GO:000963615 | Endometrium | EEC | response to toxic substance | 54/2168 | 262/18723 | 1.65e-05 | 3.18e-04 | 54 |
| GO:009886915 | Endometrium | EEC | cellular oxidant detoxification | 27/2168 | 101/18723 | 2.17e-05 | 3.89e-04 | 27 |
| GO:004545414 | Endometrium | EEC | cell redox homeostasis | 12/2168 | 35/18723 | 3.63e-04 | 3.95e-03 | 12 |
| GO:009875415 | Endometrium | EEC | detoxification | 32/2168 | 152/18723 | 5.52e-04 | 5.52e-03 | 32 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |